Virchows Archiv

, Volume 453, Issue 2, pp 165–170

Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer

  • Sven Gunia
  • Matthias May
  • Katharina Scholmann
  • Stephan Störkel
  • Bernd Hoschke
  • Stefan Koch
  • Manfred Dietel
  • Glen Kristiansen
Original Article

Abstract

Alpha-methylacyl-CoA racemase (AMACR, p504S), an enzyme involved in cellular energy metabolism by the oxidation of branched-chain fatty acids, is a biomarker that is known to be overexpressed in prostatic and colorectal carcinoma as well as in papillary renal cell carcinoma. We aimed to correlate its immunohistochemically detected expression with histopathological grading in noninvasive bladder cancer in order to hint at a so far unknown role of AMACR in the pathobiology of this tumor entity. Therefore, a cohort of 163 patients (mean age 65.3 years) diagnosed with noninvasive bladder cancer was immunohistochemically investigated in terms of AMACR expression. There was variable positive AMACR staining in 52 (31.9%) of the cases investigated. All tumors were graded by three independent clinical histopathologists according to the 1973 World Health Organization (WHO) and the 1998 WHO/International Society of Urological Pathology (ISUP) system. We found a significant positive correlation between AMACR expression and higher tumor grades using both histopathologic grading schemes. These novel findings clearly allow including high-grade noninvasive bladder carcinomas in the group of AMACR-positive neoplasms and might reflect a so far unknown role of AMACR racemase in the pathobiology and tumor cell energy metabolism of the latter tumor entity.

Keywords

Pathobiology of noninvasive bladder cancer Histopathologic grading schemes Alpha-methylacyl-CoA racemase 

References

  1. 1.
    Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang WY, Hayes RB (2007) Variants in the alpha-methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma. Cancer Epidemiol Biomark Prev 16:1536–1542CrossRefGoogle Scholar
  2. 2.
    Dorer R, Odze RD (2006) AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett’s esophagus. Am J Surg Pathol 30:871–877PubMedCrossRefGoogle Scholar
  3. 3.
    Hameed O, Humphrey PA (2005) Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 22:88–104PubMedCrossRefGoogle Scholar
  4. 4.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96PubMedCrossRefGoogle Scholar
  5. 5.
    Jiang Z, Fanger GR, Banner BF, Woda BA, Algate P, Dresser K, Xu J, Reed SG, Rock KL, Chu PG (2003) A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev 27:422–426PubMedCrossRefGoogle Scholar
  6. 6.
    Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847PubMedCrossRefGoogle Scholar
  7. 7.
    Lin A, Weiser MR, Klimstra DS, Paty PB, Tang LH, Al-Ahmadie H, Hoo Park S, Guillem JG, Temple L, Wong WD, Gerald WL, Shia J (2007) Differential expression of alpha-methylacyl-coencyme A racemase in colorectal carcinoma bears clinical and pathologic significance. Hum Pathol 38:850–856PubMedCrossRefGoogle Scholar
  8. 8.
    Lisovsky M, Falkowski O, Bhuiya T (2006) Expression of alpha-methylacyl-coencyme A racemase in dysplastic Barrett’s epithelium. Hum Pathol 37:1601–1606PubMedCrossRefGoogle Scholar
  9. 9.
    Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R (2000) Red meat and colon cancer: dietary haem, but not fat, has cytotoxic and hyperproliferative effects on rat colonic epithelium. Carcinogenesis 21:1909–1915PubMedCrossRefGoogle Scholar
  10. 10.
    Skinnider BF, Oliva E, Young RH, Amin MB (2004) Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Surg Pathol 28:701–705PubMedCrossRefGoogle Scholar
  11. 11.
    Sobin LH, Wittekind CH (1997) TNM classification of malignant tumors, 5th edn. Wiley-Liss, New York, pp 187–190Google Scholar
  12. 12.
    Suh N, Yang XJ, Tretiakova MS, Humphrey PA, Wang HL (2005) Value of CDX2, villin, and alpha-methylacyl coencyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 18:1217–1222PubMedCrossRefGoogle Scholar
  13. 13.
    Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG (2003) Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 34:792–796PubMedCrossRefGoogle Scholar
  14. 14.
    Went PT, Sauter G, Oberholzer M, Bubendorf L (2006) Abundant expression of AMACR in many distinct tumour types. Pathology 38:426–432PubMedCrossRefGoogle Scholar
  15. 15.
    Karakök M, Aydin A, Bakir K, Ucak R, Korkmaz C (2001) AgNOR/P53 expression compared with different grades in bladder carcinomas. Int Urol Nephrol 33:353–355PubMedCrossRefGoogle Scholar
  16. 16.
    Vatne V, Maartmann-Moe H, Hoestmark J (1995) The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Scand J Urol Nephrol 29:491–495PubMedCrossRefGoogle Scholar
  17. 17.
    Krüger S, Müller H (1995) Correlation of morphometry, nucleolar organizerregions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 75:480–484PubMedGoogle Scholar
  18. 18.
    Visca P, Sebastiani V, Pizer ES, Botti C, De Carli P, Filippi S, Monaco S, Alo PL (2003) Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res 23:335–339PubMedGoogle Scholar
  19. 19.
    Turyn J, Schlichtholz B, Dettlaff-Pokora A, Presler M, Goyke E, Matuszewski M, Kmiec Z, Krajka K, Swierczynski J (2003) Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer. Horm Metab Res 35:565–569PubMedCrossRefGoogle Scholar
  20. 20.
    Zha S, Ferdinadusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB (2005) Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63:316–323PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sven Gunia
    • 1
  • Matthias May
    • 2
  • Katharina Scholmann
    • 3
  • Stephan Störkel
    • 4
  • Bernd Hoschke
    • 2
  • Stefan Koch
    • 1
  • Manfred Dietel
    • 3
  • Glen Kristiansen
    • 5
  1. 1.Department of Pathology, HELIOS Klinikum Bad SaarowCharité-University Medicine Teaching HospitalBad SaarowGermany
  2. 2.Department of Urology, Carl-Thiem Klinikum CottbusCharité-University Medicine Teaching HospitalCottbusGermany
  3. 3.Department of Pathology, Campus Charité MitteCharité-University MedicineBerlinGermany
  4. 4.Department of Pathology, HELIOS Klinikum WuppertalUniversity Witten/HerdeckeWuppertalGermany
  5. 5.Department of Surgical PathologyUniversity Hospital ZürichZürichSwitzerland

Personalised recommendations